The Centers for Medicare & Medicaid Services has announced that it will cover diagnostic laboratory tests using Next Generation Sequencing for patients with advanced cancer.
Independent community oncologists play a vital role in cancer treatment for hundreds of thousands of Americans.
Lenvatinib mesylate (Lenvima) will be developed and commercialized in a collaboration between its creator, Japan’s Eisai Co. Ltd, and Merck.
Among community oncology practices, the US Pharmacopeia Convention’s General Chapter <800> draft guidelines have already raised the bar for hazardous drug management and imposed costs for compliance.
Doctors from Intermountain Healthcare decided to see if they could improve outcomes of patients placed on expensive machines.
The FDA has approved Lutathera for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Fewer than 4% of patients with cancer in the United States participate in clinical trials, the elderly and individuals with clinically relevant comorbidities are strikingly underrepresented in the research portfolio.
The debate continues to rage over whether the difference in the cost of oncologic care between outpatient hospital and physician private offices is appropriate.
Kathryn F. Mileham, MD, discusses the development of biomarker testing for patients with mutated non-small cell lung cancer.
In patients with common solid tumors, it is well-established that those with early-stage cancers have a statistically defined superior prognosis compared with those who present with and are required to be treated at later stages of the disease.